Forcing Cancer to Grow Up: Dana-Farber Scientists Reprogram Tumors to Behave Normally <p>Cancer can make its way through the body by shapeshifting through even the narrowest places, like a skilled driver navigating traffic. It has a sly way of adapting to its environment by finding detours around every blockade clinicians place in its path.   A study from the lab of Nilay Sethi, MD, PhD, in Dana-Farber’s Center ... <a class="read-more" href="https://blog.dana-farber.org/insight/2025/11/forcing-cancer-to-grow-up-dana-farber-scientists-reprogram-tumors-to-behave-normally/" title="Forcing… Dana-Farber Cancer Institute November 4, 2025 Original source
<![CDATA[Muscle RNome Analysis Reveals 2 Molecular Subtypes Associated With Cancer Cachexia ]]> Cancer Network November 3, 2025 Original source
<![CDATA[Forming CUTNETs: A Joint Venture Between Surgery and Oncology in NETs]]> Cancer Network November 3, 2025 Original source
<![CDATA[Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer]]> Cancer Network November 3, 2025 Original source
<![CDATA[Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL]]> Cancer Network November 3, 2025 Original source
<![CDATA[Short-Course Radiation May Be Feasible in Older Rectal Cancer Population]]> Cancer Network November 3, 2025 Original source
Ancient viruses hidden inside bacteria could help defeat modern infections Penn State scientists uncovered an ancient bacterial defense where dormant viral DNA helps bacteria fight new viral threats. The enzyme PinQ flips bacterial genes to create protective proteins that block infection. Understanding this mechanism could lead to breakthroughs in antivirals, antibiotic alternatives, and industrial microbiology. ScienceDaily Cancer November 3, 2025 Original source
<![CDATA[Overview of the ADVANCE Study: Methodology and Design]]> Cancer Network November 3, 2025 Original source
<![CDATA[How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap]]> Cancer Network November 3, 2025 Original source
<![CDATA[Pretesting Prior to Quad Therapy for NDMM]]> Cancer Network November 3, 2025 Original source
Three Ways Research Could Improve Pancreatic Cancer Treatment <p>Pancreatic cancer has long been difficult to detect and treat. Dana-Farber experts in the  Hale Family Center for Pancreatic Cancer Research, however, are working to change that with research efforts in three key areas that are poised to advance early detection, early intervention, and treatment of the disease.   They presented these topics for discussion with ... <a class="read-more" href="https://blog.dana-farber.org/insight/2025/11/three-ways-research-could-improve-pancreatic-cancer-treatment/" title="Three… Dana-Farber Cancer Institute November 3, 2025 Original source
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study Background <p>In the PAPILLON study, first-line amivantamab-chemotherapy in epidermal growth factor receptor (<i>EGFR)</i> exon 20 insertion-mutated non-small cell lung cancer demonstrated significantly prolonged progression-free survival and favorable overall survival over chemotherapy; a consistent benefit was also observed across some secondary endpoints. However, the complete clinical benefit of first-line amivantamab-chemotherapy is not fully understood, nor is the survival advantage in the… Targeted Oncology November 3, 2025 Original source
The Efficacy and Safety of Beta-blockers and Immune Checkpoint Inhibitors in Patients with Cancer: A Systematic Review and Meta-analysis Background <p>Immune checkpoint inhibitors (ICIs) are now standard for various cancers, and preclinical studies suggest beta-blockers (BBs) may boost the efficacy of ICIs. However, prior clinical studies had small sample sizes, requiring large-scale validation.</p> Objective <p>We aimed to evaluate the efficacy and safety of combining BBs with ICIs in patients with solid tumors through a systematic review and meta-analysis.</p> Methods… Targeted Oncology November 1, 2025 Original source
Cancer centers adapt to life without site visits as NIH changes CCSG review <p>Love them or hate them, site visits have been a part of the culture of NCI-designated cancer centers for decades, shaping the process for admitting members to the elite club and influencing internal politics within institutions. This content is for Group 1 - Individual Seat, Individual Subscription - Annual ($555), Individual Subscription - Monthly ($55), […]</p> <p>The post <a href="https://cancerletter.com/nci/20251031_1/"… The Cancer Letter October 31, 2025 Original source
Class action complaint alleging GRAIL insider fraud resubmitted after dismissal <p>Following last month’s dismissal of the securities class action complaint against Illumina Inc. and its former spinoff company, GRAIL, the plaintiffs have refiled an amended complaint, keeping the action alive.  This content is for Group 1 - Individual Seat, Individual Subscription - Annual ($555), Individual Subscription - Monthly ($55), Introductory Subscription - non-renewing ($60), and […]</p> <p>The post <a href="https://cancerletter.com/clinical/20251031_2/"… The Cancer Letter October 31, 2025 Original source
Friends publishes three white papers ahead of annual meeting <p>The Friends of Cancer Research annual meeting, to be held Nov. 4 in Washington, DC, will focus on three questions facing the field of oncology clinical trial design:  How do clinical researchers create seamless trial designs for drug development in rare cancers? What are the considerations for clinical trial design testing combination drug development?  How […]</p> <p>The post <a href="https://cancerletter.com/the-cancer-letter/20251031_3/"… The Cancer Letter October 31, 2025 Original source
How GLP-1RA drugs are reshaping patient physiology and the future of oncology <p>The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. […]</p> <p>The post <a href="https://cancerletter.com/trials-and-tribulations/20251031_4/"… The Cancer Letter October 31, 2025 Original source
Paychecks stop for HHS workers as shutdown continues <p>The federal government shutdown is entering its fifth week, and funding delays are now directly affecting the healthcare system. This content is for Group 1 - Individual Seat, Individual Subscription - Annual ($555), Individual Subscription - Monthly ($55), Introductory Subscription - non-renewing ($60), and Sponsored account members only. Visit the site and log in/register to […]</p> <p>The post <a href="https://cancerletter.com/cancer-policy/20251031_5a/"… The Cancer Letter October 31, 2025 Original source
NEJM, public health group to launch alternate publication to CDC’s MMWR <p>Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report, often called “the voice of the CDC,” now has an rival publication.  This content is for Group 1 - Individual Seat, Individual Subscription - Annual ($555), Individual Subscription - Monthly ($55), Introductory Subscription - non-renewing ($60), and Sponsored account members only. Visit the site […]</p> <p>The post <a href="https://cancerletter.com/cancer-policy/20251031_5b/"… The Cancer Letter October 31, 2025 Original source
Senators, nonprofits respond to Trump’s avowed support for IVF <p>Last week, President Donald Trump announced a deal with pharmaceutical company Merck KGaA and its U.S. subsidiary, EMD Serono, to sharply reduce the cost of some fertility drugs used for in-vitro fertilization, in exchange for a three-year reprieve on some of the tariffs levied on pharmaceutical imports (The Cancer Letter, Oct. 24, 2025). This content […]</p> <p>The post <a href="https://cancerletter.com/cancer-policy/20251031_5c/"… The Cancer Letter October 31, 2025 Original source